Phio Pharmaceuticals adds dermatologist to its board of directors

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) has appointed R. Todd Plott, M.D., to its board of directors, the clinical-stage biopharmaceutical company announced.

Dr. Plott is a board-certified dermatologist with more than 30 years of experience in dermatologic care. He has overseen hundreds of clinical trials and served on the FDA Dermatologic and Ophthalmic Drug Advisory Committee from 2016 to 2021. He currently operates a private practice focused on complex skin diseases, acne, and skin cancer.

Robert Bitterman, CEO and Chairman of the Board, said Dr. Plott's dermatology practice experience and clinical development expertise provide "a valuable resource to Phio as we advance PH-762 for squamous cell carcinoma."

Phio is developing PH-762, an siRNA compound that silences the PD-1 gene implicated in various forms of skin cancer. The company completed a Phase 1b trial evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.

You May Also Be Interested In

• U.S. debt tops $40 trillion
• Ocean Power Technologies revises fiscal 2026 results after audit
• Sera Prognostics names Scott Gleason as CFO, effective Aug. 31